These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 18729085)

  • 21. The growth hormone-releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line.
    Annunziata M; Grande C; Scarlatti F; Deltetto F; Delpiano E; Camanni M; Ghigo E; Granata R
    Fertil Steril; 2010 Aug; 94(3):841-9. PubMed ID: 19524226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
    Kanashiro CA; Schally AV; Zarandi M; Hammann BD; Varga JL
    Int J Oncol; 2007 Apr; 30(4):1019-28. PubMed ID: 17332943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Cai RZ; Baker B; Hammann BD; Armatis P; Kanashiro CA
    Eur J Cancer; 2005 Nov; 41(17):2735-44. PubMed ID: 16291086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II.
    Braczkowski R; Schally AV; Plonowski A; Varga JL; Groot K; Krupa M; Armatis P
    Cancer; 2002 Oct; 95(8):1735-45. PubMed ID: 12365022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K
    Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
    Halmos G; Schally AV; Czompoly T; Krupa M; Varga JL; Rekasi Z
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4707-14. PubMed ID: 12364462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
    Seitz S; Hohla F; Schally AV; Moder A; Engel JB; Horn F; Varga J; Zarandi M; Ortmann O; Köster F; Buchholz S
    Oncol Rep; 2008 Nov; 20(5):1289-94. PubMed ID: 18949435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
    Zarandi M; Varga JL; Schally AV; Horvath JE; Toller GL; Kovacs M; Letsch M; Groot K; Armatis P; Halmos G
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4610-5. PubMed ID: 16537407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
    Kahán Z; Varga JL; Schally AV; Rékási Z; Armatis P; Chatzistamou L; Czömpöly T; Halmos G
    Breast Cancer Res Treat; 2000 Mar; 60(1):71-9. PubMed ID: 10845811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
    Jungwirth A; Schally AV; Pinski J; Halmos G; Groot K; Armatis P; Vadillo-Buenfil M
    Br J Cancer; 1997; 75(11):1585-92. PubMed ID: 9184172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly.
    Kovacs M; Kineman RD; Schally AV; Zarandi M; Groot K; Frohman LA
    Endocrinology; 1997 Nov; 138(11):4536-42. PubMed ID: 9348175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas.
    Halmos G; Schally AV; Bernardino AL; Varga JL
    Int J Oncol; 2006 Aug; 29(2):463-9. PubMed ID: 16820890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors.
    Lamharzi N; Schally AV; Koppán M; Groot K
    Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8864-8. PubMed ID: 9671770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
    Letsch M; Schally AV; Busto R; Bajo AM; Varga JL
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor.
    Barabutis N; Siejka A; Schally AV; Block NL; Cai R; Varga JL
    J Mol Endocrinol; 2010 Feb; 44(2):127-34. PubMed ID: 19897610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma.
    Jungwirth A; Schally AV; Pinski J; Groot K; Armatis P; Halmos G
    Proc Natl Acad Sci U S A; 1997 May; 94(11):5810-3. PubMed ID: 9159156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
    Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
    Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
    Hohla F; Schally AV; Szepeshazi K; Varga JL; Buchholz S; Köster F; Heinrich E; Halmos G; Rick FG; Kannadka C; Datz C; Kanashiro CA
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14513-8. PubMed ID: 16983095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
    Xu X; Kreye E; Kuo CB; Walker AM
    Cancer Res; 2001 Aug; 61(16):6098-104. PubMed ID: 11507059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diallyl trisulfide suppresses growth of PC-3 human prostate cancer xenograft in vivo in association with Bax and Bak induction.
    Xiao D; Lew KL; Kim YA; Zeng Y; Hahm ER; Dhir R; Singh SV
    Clin Cancer Res; 2006 Nov; 12(22):6836-43. PubMed ID: 17121905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.